NDRA · XBRL financial data

ENDRA Life Sciences financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NDRA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,633	579*	1,042	716	794	638*	529	381	432	508*	776	234
General and administrative	1,253	731*	1,500	1,352	631	3,573*	872	851	893	1,108*	1,393	1,244
Total operating expenses	3,129	1,458*	2,781	2,231	1,509	4,297*	1,469	1,301	1,371	1,622*	2,174	1,483
Operating income (loss)	(3,129)	(1,458)*	(2,781)	(2,231)	(1,509)	(4,297)*	(1,469)	(1,301)	(1,371)	(1,622)*	(2,174)	(1,483)
Other income (expense)	28	(2)*	(5)	2	(66)	(619)*	24	13	42	—	—	—
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	—	—	—	—
Net income (loss)	(3,101)	(1,460)*	(2,776)	(2,229)	(2,354)	(4,149)*	(1,036)	(1,226)	(1,596)	(3,169)*	(1,311)	160
Earnings per share, basic USD per share	—	—	—	—	(9.54)	—	(1.86)	(1.71)	(2.10)	—	(1.09)	0.12
Earnings per share, diluted USD per share	—	—	—	—	(9.54)	—	(1.86)	(1.71)	(2.10)	—	(1.09)	0.06
Weighted average shares, basic thousands of shares	—	—	—	—	247	—	558	717	761	—	1,200	1,324
Weighted average shares, diluted thousands of shares	—	—	—	—	247	—	558	717	761	—	1,200	2,475

† Share count changed about 1/135 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (NDRA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	3,335	2,834	1,135	6,401	4,745	3,229	2,065	1,809	794	762	356	1,740
Inventory	2,758	2,623	2,712	2,712	2,712	0	0	0	0	0	—	—
Total current assets	6,398	3,033	1,271	6,713	4,962	3,434	2,180	1,853	1,049	968	537	5,587
Property and equipment, net	161	112	111	92	80	69	73	63	53	43	33	44
Right-of-use asset	393	354	314	272	230	578	546	520	491	462	432	401
Total assets	7,603	6,754	5,061	10,443	8,379	4,452	3,171	2,808	1,964	3,854	3,438	7,942
Accounts payable	419	360	522	300	279	270	224	282	252	383	457	465
Accrued liabilities	—	—	—	—	—	—	—	—	—	162	92	10
Total current liabilities	2,169	903	1,217	1,350	814	605	566	577	800	751	835	787
Lease liability, non-current	237	192	146	98	50	487	461	429	397	363	327	291
Total liabilities	2,407	1,095	1,363	1,449	1,774	1,892	1,418	1,335	1,793	1,594	1,651	1,633
Accumulated deficit	(90,471)	(91,930)	(94,706)	(96,935)	(99,289)	(103,438)	(104,474)	(105,700)	(107,296)	(110,466)	(111,777)	(111,617)
Total stockholders' equity	5,196	5,659	3,698	8,994	6,605	2,560	1,753	1,473	171	2,260	1,787	6,310
Total liabilities and equity	7,603	6,754	5,061	10,443	8,379	4,452	3,171	2,808	1,964	3,854	3,438	7,942
Common shares outstanding (cover page) thousands of shares	8,455	11,036	11,036	72,440	537	562	738	753	1,166	1,241	1,270	1,500

† Share count changed about 1/135 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (NDRA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24†Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,101)	(1,460)*	(2,776)	(2,229)	(2,354)	(4,149)*	(1,036)	(1,226)	(1,596)	(3,169)*	(1,311)	160
Stock-based compensation	253*	251*	317	187*	(37)*	105*	83	40	145*	13*	574	542*
Depreciation and amortization	—	—	—	—	—	11*	14	9*	11*	10*	9	8*
Net cash from operating activities	(2,599)*	(2,175)*	(2,144)	(2,083)*	(1,657)*	(1,516)*	(1,293)	(1,114)*	(1,164)*	(1,612)*	(1,120)	(928)*
Purchases of property and equipment	0*	7*	27	(11)*	0*	0*	17	0*	0*	0*	—	—
Net cash from investing activities	0*	2*	(24)	11*	0*	0*	(17)	0*	0*	(3,000)*	450	2,217*
Proceeds from issuing common stock	1,114*	657*	420	729*	0*	0*	146	857*	149*	66*	264	94*
Repayments of long-term debt	—	—	28	0*	0*	—	0	0*	—	—	—	—
Net cash from financing activities	1,114*	1,672*	469	7,338*	2*	0*	146	857*	149*	4,580*	264	3,894*

† Share count changed about 1/135 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
ENDRA Life Sciences	1,740	not reported	(928)*	1.5M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Global Innovative Platforms	244	51	(134)*	49.8M	1.8 quarters	Q3 FY26 10-QJun 30, 2026
Interpace Biosciences	2,688	9,131	98*	27.7M	—	Q2 FY26 10-QJun 30, 2026
Bluejay Diagnostics	9,599	not reported	(1,499)*	4.5M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Stimcell Energetics	6.9	not reported	(109)	21.1M	0.1 quarters	Q1 FY27 10-QAug 31, 2026
LogicMark	3,496	3,349	83*	899,759	—	Q2 FY26 10-QJun 30, 2026
Nu-Med Plus	5.4	0	1.1*	83.5M	—	Q2 FY26 10-QJun 30, 2026
INVO Fertility	3,733	2,175	(1,101)*	2.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
STRATA Skin Sciences	7,912	9,292*	(239)*	5.9M	33.1 quarters	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.